Cargando…

Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis

BECKGROUND: The association of MGMT (O(6)-methyguanine deoxyribonucleic acid methyltransferase) promoter hypermethylation with gastric cancer (GC) risk has been studied extensively, but the results remained unclear. Here, we performed a meta-analysis to evaluate whether promoter hypermethylation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zongxin, Xin, Shaojun, Gao, Min, Cai, Yunxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413244/
https://www.ncbi.nlm.nih.gov/pubmed/28445279
http://dx.doi.org/10.1097/MD.0000000000006708
_version_ 1783233149056057344
author Zhang, Zongxin
Xin, Shaojun
Gao, Min
Cai, Yunxiang
author_facet Zhang, Zongxin
Xin, Shaojun
Gao, Min
Cai, Yunxiang
author_sort Zhang, Zongxin
collection PubMed
description BECKGROUND: The association of MGMT (O(6)-methyguanine deoxyribonucleic acid methyltransferase) promoter hypermethylation with gastric cancer (GC) risk has been studied extensively, but the results remained unclear. Here, we performed a meta-analysis to evaluate whether promoter hypermethylation of the MGMT gene contributed to gastric pathogenesis. METHODS: Relevant studies were identified by retrieving the PubMed, Web of Science, Embase, and China National Knowledge Infrastructure (CNKI) databases. The Newcastle–Ottawa Scale was applied to assess methodological quality of the included studies. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to evaluate the association of MGMT promoter hypermethylation with gastric pathogenesis. Moreover, STATA 12.0 software was used to summarize the extracted data in this meta-analysis. RESULTS: Seventeen studies, comprising 1736 cases and 1291 controls, were included in this meta-analysis. The frequency of MGMT promoter hypermethylation in the GC group (32.97%) was significantly higher than those in the control group (18.00%) (OR = 2.83, CI = 1.93–4.15, P < .05). When stratified by cancer subtype, the results indicated that the frequency of MGMT promoter hypermethylation was significantly higher in gastric adenocarcinoma than in control group (OR = 3.47, CI = 1.06–11.35, P < .05). In addition, MGMT promoter hypermethylation significantly promoted distant metastasis and lymph node (LN) metastasis of gastric tumor (for distant metastasis, OR = 4.22, CI = 2.42–7.37, P < .05; for LN metastasis, OR = 1.56, CI = 1.14–2.13, P < .05). A significant association between MGMT promoter hypermethylation and TNM-stage was also found in the present meta-analysis (OR = 2.70, CI = 1.79–4.08, P < .05). CONCLUSION: The results of this meta-analysis suggested that MGMT gene-promoter hypermethylation was significantly associated with an increased risk of GC, especially in Asians. Furthermore, MGMT gene-promoter hypermethylation might be correlated with the distant metastasis and LN metastasis of GC.
format Online
Article
Text
id pubmed-5413244
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-54132442017-05-05 Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis Zhang, Zongxin Xin, Shaojun Gao, Min Cai, Yunxiang Medicine (Baltimore) 5700 BECKGROUND: The association of MGMT (O(6)-methyguanine deoxyribonucleic acid methyltransferase) promoter hypermethylation with gastric cancer (GC) risk has been studied extensively, but the results remained unclear. Here, we performed a meta-analysis to evaluate whether promoter hypermethylation of the MGMT gene contributed to gastric pathogenesis. METHODS: Relevant studies were identified by retrieving the PubMed, Web of Science, Embase, and China National Knowledge Infrastructure (CNKI) databases. The Newcastle–Ottawa Scale was applied to assess methodological quality of the included studies. Pooled odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated to evaluate the association of MGMT promoter hypermethylation with gastric pathogenesis. Moreover, STATA 12.0 software was used to summarize the extracted data in this meta-analysis. RESULTS: Seventeen studies, comprising 1736 cases and 1291 controls, were included in this meta-analysis. The frequency of MGMT promoter hypermethylation in the GC group (32.97%) was significantly higher than those in the control group (18.00%) (OR = 2.83, CI = 1.93–4.15, P < .05). When stratified by cancer subtype, the results indicated that the frequency of MGMT promoter hypermethylation was significantly higher in gastric adenocarcinoma than in control group (OR = 3.47, CI = 1.06–11.35, P < .05). In addition, MGMT promoter hypermethylation significantly promoted distant metastasis and lymph node (LN) metastasis of gastric tumor (for distant metastasis, OR = 4.22, CI = 2.42–7.37, P < .05; for LN metastasis, OR = 1.56, CI = 1.14–2.13, P < .05). A significant association between MGMT promoter hypermethylation and TNM-stage was also found in the present meta-analysis (OR = 2.70, CI = 1.79–4.08, P < .05). CONCLUSION: The results of this meta-analysis suggested that MGMT gene-promoter hypermethylation was significantly associated with an increased risk of GC, especially in Asians. Furthermore, MGMT gene-promoter hypermethylation might be correlated with the distant metastasis and LN metastasis of GC. Wolters Kluwer Health 2017-04-28 /pmc/articles/PMC5413244/ /pubmed/28445279 http://dx.doi.org/10.1097/MD.0000000000006708 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5700
Zhang, Zongxin
Xin, Shaojun
Gao, Min
Cai, Yunxiang
Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis
title Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis
title_full Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis
title_fullStr Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis
title_full_unstemmed Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis
title_short Promoter hypermethylation of MGMT gene may contribute to the pathogenesis of gastric cancer: A PRISMA-compliant meta-analysis
title_sort promoter hypermethylation of mgmt gene may contribute to the pathogenesis of gastric cancer: a prisma-compliant meta-analysis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413244/
https://www.ncbi.nlm.nih.gov/pubmed/28445279
http://dx.doi.org/10.1097/MD.0000000000006708
work_keys_str_mv AT zhangzongxin promoterhypermethylationofmgmtgenemaycontributetothepathogenesisofgastriccanceraprismacompliantmetaanalysis
AT xinshaojun promoterhypermethylationofmgmtgenemaycontributetothepathogenesisofgastriccanceraprismacompliantmetaanalysis
AT gaomin promoterhypermethylationofmgmtgenemaycontributetothepathogenesisofgastriccanceraprismacompliantmetaanalysis
AT caiyunxiang promoterhypermethylationofmgmtgenemaycontributetothepathogenesisofgastriccanceraprismacompliantmetaanalysis